We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Breakthrough Genetic Map Advances Understanding of Bone Disorders

By LabMedica International staff writers
Posted on 14 Jul 2026

Skeletal disorders such as osteoporosis and osteoarthritis are widespread in older adults and can arise alongside rare bone conditions and cancers that spread to bone. More...

Many existing treatments primarily slow further loss, highlighting a critical gap in strategies that rebuild damaged tissue. Pinpointing which cells and genes orchestrate bone turnover has been hampered by the complexity of bone and marrow. New research now demonstrate a detailed genetic map of bone-regulating cells that addresses this challenge.

Garvan Institute of Medical Research (Sydney, Australia) and collaborators have produced what they describe as the most detailed map to date of the cells and genes that regulate bone formation and loss, published in Nature Genetics on July 10, 2026. The team focused on the interface between hard bone and bone marrow, using single-cell RNA sequencing (scRNA-seq) to determine which genes are active in individual cells. Their analysis delineated 34 distinct cell groups and defined the gene programs operating within each.

The researchers integrated this cell-by-cell map with genetic and bone density data from approximately 500,000 participants in the UK Biobank. This multiscale approach identified hundreds of genes linked to bone health, with more than half not previously associated with maintaining the skeleton. Cells surrounding blood vessels emerged as key, previously underappreciated contributors to bone repair and turnover.

The resource was used to pinpoint disease-relevant cell types for both rare and common skeletal disorders, including osteogenesis imperfecta and osteoporosis. According to the institutions, the findings fundamentally enhance understanding of skeletal disease biology and create a shortlist of targets for interrogating pathogenesis. The data have been made accessible to researchers worldwide via an open access platform.

The work involved teams from the Garvan Institute of Medical Research, Mater Research, and Imperial College London. By combining high-resolution cell mapping with population-scale genetics, the study provides a framework for linking human genomic variation to specific bone cell functions and disease processes.

“Most people don't realise that bones are constantly changing – the human body replaces its skeleton every 10 years or so. This is a hugely important process, but until now we've had a very limited understanding of the cells and mechanisms that control this turnover of bone. Most of the drugs now available focus only on halting bone disease, rather than rebuilding lost bone, which is really important for reversing damage,” said Peter Croucher, Professor, Garvan Institute of Medical Research.

“We hope that sharing this knowledge can speed up development of new therapies that prevent diseases like osteoporosis and reverse the damage caused by them,” said John Kemp, Associate Professor, Mater Research.

Related Links
Garvan Institute of Medical Research


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Pipette Calibration System
Artel PCS®
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.